Editorial on the Research Topic An Update on Pediatric Skeletal System InfectionsOsteoarticular infections (OAIs) in pediatric patients are medical emergencies that require early diagnosis and adequate treatment to avoid severe septic complications, prolonged morbidity, and long-term functional disability (1). Although traumatic inoculation of bacteria into the joint space and bones or dissemination from a contiguous soft tissue focus may occur, in most cases, pathogens reach the skeletal tissues through the hematogenous route (2). Because the incidence of bacteremia is elevated in immunologically naïve young children, the incidence of septic arthritis and osteomyelitis is higher in early childhood (1).Early diagnosis of skeletal infections, identification of their etiologic agent, and prompt administration of adequate antimicrobial therapy are cornerstones of managing the disease, avoiding clinical deterioration, and preventing permanent orthopedic sequelae (3). Traditionally, culture isolation of the etiologic agent, its identification, and determination of its antibiotic susceptibility was performed by conventional methods. However, causative organisms may be present in the specimen at low concentrations, difficult to isolate, and/or children may have been empirically administered antibiotics before cultures were obtained. Consequently, many pediatric joint and bone infections remained bacteriologically unconfirmed (4). Because the microbiology laboratory results are obtained with a 2-3-day delay and the danger of administering an inappropriate or poorly efficient antibiotic, the initial therapy of bone and joint infections usually consists of wide-spectrum antimicrobial drugs, including those that provide appropriate coverage of Staphylococcus aureus (3). To ensure therapeutic success, antibiotics are administered through the intravenous route in the early phase and switched to oral therapy after body temperature has normalized for 24 h, local findings and motion have improved, and C-reactive protein (CRP) levels have decreased (1).Technological progress has revolutionized the epidemiology, diagnosis, and management of pediatric OAI in recent decades, as summarized in Table 1.The present Special Issue provides an update on managing these skeletal system infections in children and the areas of controversy and current research to improve the diagnosis, shorten the duration of intravenous therapy, and reduce hospitalization length.The article by Porsch et al. summarizes our current knowledge of the virulence factors of Kingella kingae. Advances in the culture methods and especially the increasing use of molecular detection methods have resulted in recognition of the bacterium as the prime etiology of hematogenous septic arthritis, osteomyelitis, spondylodiscitis, and tenosynovitis in children aged 6-48 months (8). Intensive research conducted over the last two decades has